Survival Benefit Observed With Nimotuzumab Plus Chemo in KRAS Wild-Type Advanced Pancreatic CancerJune 4th 2022
Patients with KRAS wild-type pancreatic cancer elicited a significant survival benefit with the addition of nimotuzumab to gemcitabine vs placebo plus gemcitabine in a phase 3 trial.
FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCCMay 27th 2022
Nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab received FDA approval as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status
2022 ASCO Gastrointestinal Cancers Symposium HighlightsApril 20th 2022
Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.
Adjuvant Capecitabine Continues as Mainstay in Biliary Tract Cancer, But More Research Is Needed in Neoadjuvant SettingApril 19th 2022
A long-term analysis of the phase 3 BILCAP study highlighted modest benefit for patients with resected biliary tract cancer who received capecitabine following surgery.
Pretreatment With Temozolomide, Immunotherapy Combo Elicits Encouraging Responses in MSS and MGMT-Silenced mCRCApril 3rd 2022
The addition of temozolomide to a low-dose treatment plan of ipilimumab and nivolumab extended progression-free survival among patients with metastatic colorectal cancer.
Patients With Treatment-Naïve RCC Achieve Superior QoL With Nivolumab/CabozantinibJanuary 29th 2022
Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.
Adding Nivolumab to Encorafenib/Cetuximab Yields High Response Rates in MSS, BRAF V600E+ CRCJanuary 24th 2022
Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.
Pembrolizumab Plus Chemotherapy Maintains QOL, Tolerability in Esophageal Cancer/GEJ AdenocarcinomaJanuary 24th 2022
In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.
Trastuzumab Deruxtecan Significantly Improves OS in Select Gastric/GEJ CancerJanuary 22nd 2022
Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.
Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ AdenocarcinomaJanuary 21st 2022
Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.
Gut Microbiome May Be Useful in Predicting Toxicities With Nivolumab in Advanced Gastric CancerJanuary 21st 2022
The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events (AEs) in patients with advanced gastric cancer.
Patients With Biliary Tract Cancers Benefit From Durvalumab Plus ChemotherapyJanuary 20th 2022
Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.